BioCryst Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
JMP Securities Downgrades BioCryst Pharma (BCRX) to Market Perform
August 4, 2016 9:58 AM EDTJMP Securities downgraded BioCryst Pharma (NASDAQ: BCRX) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.
Shares of BioCryst Pharma closed at $4.03 yesterday.
... MoreBioCryst Pharma (BCRX) Tops Q2 EPS by 4c
August 4, 2016 8:35 AM EDTBioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.22), $0.04 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $4.8 million versus the consensus estimate of $3.92 million.
Cash, cash equivalents and investments decreased to $64.3 million at June 30, 2016, as compared to $100.9 million at... More
